LAURA HARSH: Open Payments
NPI 1225326184 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,349 in 53 payments from 28 companies in 2025. Trend: 2023 $1,506 · 2024 $1,611 · 2025 $1,349
Food & beverage: $1,349
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $137 |
| E.R. Squibb & Sons, L.L.C. | 4 | $125 |
| Novartis Pharmaceuticals Corporation | 4 | $108 |
| Incyte Corporation | 4 | $104 |
| AstraZeneca Pharmaceuticals LP | 4 | $97 |
| Astellas Pharma US Inc | 3 | $68 |
| GENZYME CORPORATION | 2 | $62 |
| Merck Sharp & Dohme LLC | 2 | $61 |
| GlaxoSmithKline, LLC. | 2 | $52 |
| Genentech USA, Inc. | 2 | $46 |
Products named: OPDIVO, SARCLISA, KEYTRUDA, MONJUVI, KISQALI, TALVEY, RYBREVANT, JAKAFI.
Industry payments across NV — which companies pay providers there.
